ETEmily M. Traxler

Emily M. Traxler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily M. Traxler has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development

    by Snehal Nirgude, Natali S. Sobel Naveh, Sanam L. Kavari, Emily M. Traxler, Jennifer M. Kalish

    Background: Wilms tumor (WT) exhibits structural and epigenetic changes at chromosome 11p15, which also cause Beckwith-Wiedemann Syndrome (BWS). Children diagnosed with BWS have increased risk for WT. The aim of this study is to identify the molecular signaling signatures in BWS driving these tumors. Methods: We performed whole exome sequencing, methylation array analysis, and gene expression analysis on BWS-WT samples. Our data were compared to publicly available nonBWS data. We categorized WT from BWS and nonBWS patients by assessment of 11p15 methylation status and defined 5 groups– control kidney, BWS-nontumor kidney, BWS-WT, normal-11p15 nonBWS-WT, altered-11p15 nonBWS-WT. Results: BWS-WT samples showed single nucleotide variants in BCORL1, ASXL1, ATM and AXL but absence of recurrent gene mutations associated with sporadic WT. We defined a narrow methylation range stratifying nonBWS-WT samples. BWS-WT and altered-11p15 nonBWS-WT showed enrichment of common and unique molecular signatures based on global differential methylation and gene expression analysis. CTNNB1 overexpression and broad range of interactions were seen in the BWS-WT interactome study. Conclusion: While WT predisposition in BWS is well-established, as are 11p15 alterations in nonBWS-WT, this study focused on stratifying tumor genomics by 11p15 status. Further investigation of our findings may identify novel therapeutic targets in WT oncogenesis.


  • Open Access

    Abstract 6045: Methylation differences in cancer signaling pathways drive Beckwith-Wiedemann Syndrome Wilms Tumor oncogenesis

    by Natali Sobel Naveh, Emily Traxler, Snehal Nirgude, Jennifer Kalish

    Wilms Tumor (WT), or nephroblastoma, is the most common pediatric renal cancer. This cancer is thought to arise from the expansion of embryonal nephrogenic rest cell population. The most common (epi)genetic alterations in WT occur on chromosome 11p15, accounting for about 75% of WT. These same changes on chromosome 11p15 also cause one of the most common WT predisposition syndromes, Beckwith-Wiedemann Syndrome (BWS). BWS is a pediatric overgrowth disorder affecting numerous tissues including the kidney and up to 28% of patients with BWS develop cancer. As patients with BWS have the same 11p15 epigenetic and structural changes that arise sporadically in non-syndromic WT, BWS WT provides a unique opportunity to investigate the specific molecular effect and mechanism by which 11p15 causes oncogenesis. Using clinical data and patient samples from the International BWS Registry and Biorepository, we used whole exome sequencing (WES) and methylation array technologies to examine the genomic and epigenomic landscape of BWS non-tumor kidney (NT) and WT tumors compared to control kidney samples. We found several large-scale recurrent copy number alterations (CNAs) in the BWS WT cohort across cancer-associated chr1p36, WT-associated chr16q, and novel chr15q. Two BWS WT presented with an above average number of genomic alterations compared to previous sporadic WT; one had mutations in telomerase-associated genes and the other had mutations in mismatch repair pathway genes. We investigated other known cancer-associated genes affected by CNAs and single nucleotide variants (SNVs) and found BCORL1 mutations in five BWS WT. Cancer-associated pathways, including targets of TP53, CTNNB1, and MYCN, were significantly differentially methylated between BWS WT and NT. Targets of TP53 and CTNNB1 were also differentially methylated between BWS NT and controls. In addition, FOXO-regulated gene promoters were significant when comparing both BWS WT to NT and BWS NT to control methylation. Overall, WES results indicate that BWS WT have similar genomic stability compared to pediatric cancers and sporadic WT, but we did identify two hyper-mutators including a rare mismatch repair defect WT within the cohort. Recurrent mutations in genes associated with sporadic WT, such as TP53, CTNNB1, and MYCN were not present in BWS samples; however, methylation differences were observed in TP53-, CTNNB1- and MYCN-related gene sets. These and other methylation changes in BWS NT and WT may influence the transcriptome in conjunction with 11p15 alterations to promote growth and oncogenesis without coding mutations. Data presented herein suggest one way in which 11p15-altered genomes predispose cells to oncogenic transitions. Further study of non-syndromic WT methylomes as well as BWS NT and WT tissue expression are required to fully understand these effects. Citation Format: Natali Sobel Naveh, Emily Traxler, Snehal Nirgude, Jennifer Kalish. Methylation differences in cancer signaling pathways drive Beckwith-Wiedemann Syndrome Wilms Tumor oncogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6045.

  • Open Access

    Altered microRNA expression profiles in large offspring syndrome and Beckwith-Wiedemann syndrome

    by Yahan Li, Darren Erich Hagen, Tieming Ji, Mohammad Reza Bakhtiarizadeh, Whitney M. Frederic, Emily M. Traxler, Jennifer M. Kalish, Rocío Melissa Rivera

    The use of assisted reproductive technologies (ART) can induce a congenital overgrowth condition in humans and ruminants, namely Beckwith-Wiedemann syndrome (BWS) and large offspring syndrome (LOS), respectively. Shared phenotypes and epigenotypes have been found between BWS and LOS. We have observed global misregulation of transcripts in bovine foetuses with LOS. microRNAs (miRNAs) are important post-transcriptional gene expression regulators. We hypothesize that there is miRNA misregulation in LOS and that this misregulation is shared with BWS. In this study, small RNA sequencing was conducted to investigate miRNA expression profiles in bovine and human samples. We detected 407 abundant known miRNAs and predicted 196 putative miRNAs from the bovine sequencing results and identified 505 abundant miRNAs in human tongue. Differentially expressed miRNAs (DE-miRNAs) were identified between control and LOS groups in all tissues analysed as well as between BWS and control human samples. DE-miRNAs were detected from several miRNA clusters including DLK1-DIO3 genomic imprinted cluster in LOS and BWS. DNA hypermethylation was associated with downregulation of miRNAs in the DLK1-DIO3. mRNA targets of the DE-miRNAs were predicted and signalling pathways associated with control of organ size (including the Hippo signalling pathway), cell proliferation, apoptosis, cell survival, cell cycle, and cell adhesion were found to be enriched with these genes. Yes associated protein 1 (YAP1) is the core effector of the Hippo signalling pathway, and increased level of active (non-phosphorylated) YAP1 protein was detected in skeletal muscle of LOS foetuses. Overall, our data provide evidence of miRNA misregulation in LOS and BWS.